Immunome (IMNM) Current Leases (2019 - 2024)
Immunome (IMNM) posted Current Leases of $63000.0 for Q4 2024, down 75.49% on a QoQ basis from $257000.0 in Q3 2024, and down 79.68% year-over-year from $310000.0 in Q1 2024.
Immunome (IMNM) Current Leases (2019 - 2024) Analysis & Trends
Immunome's Current Leases history runs 3 years deep, the most recent figure standing at $63000.0 for Q4 2024.
- Quarterly Current Leases fell 79.68% year-over-year to $63000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $63000.0 (down 79.68% YoY) and the FY2024 annual result came in at $63000.0, down 79.68% from the prior year.
- Current Leases was $63000.0 for Q4 2024 at Immunome, down from $257000.0 in the prior quarter.
- Across five years, Current Leases topped out at $310000.0 in Q4 2023 and bottomed at $63000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 531,233.95 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 20.58 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 872,589.03 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 720.00 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 11.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.61 Mn |
| 10 | Immunome | 2.49 Bn | 1.91 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 63,000.00 |
| Sep 30, 2024 | 257,000.00 |
| Dec 31, 2023 | 310,000.00 |
| Dec 31, 2019 | 239,000.00 |